Medicare Enrolled
Dr. Ghassan Noureddine, M.D.
Pulmonary Disease · Houston, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Noureddine from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Noureddine?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Noureddine
Dr. Ghassan Noureddine is a pulmonary disease specialist in Houston, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Noureddine performed 1,945 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Noureddine received a total of $7,674 from 31 pharmaceutical and/or device companies across 339 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Noureddine is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 21% volume in TX
$7,674 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗1,945
Medicare services
Top 21% in TX for pulmonary disease
Not available
Unique patients (not deduplicated)
$80
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
370 | $96 | $277 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
368 | $64 | $177 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
318 | $99 | $265 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
124 | $43 | $231 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
122 | $46 | $245 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
105 | $31 | $302 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
98 | $176 | $2,155 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
88 | $134 | $625 |
| Inhalation treatment for airway obstruction or sputum production A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production. |
86 | $7 | $60 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing patterns, and sleep duration. This test records physiological data while you sleep to assess your sleep quality and breathing function. |
49 | $120 | $295 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
48 | $131 | $442 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
30 | $22 | $100 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
28 | $35 | $195 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
28 | $34 | $165 |
| Remote vital sign monitoring management, each additional 20 minutes This code covers the time spent by a provider managing patient data from remote vital sign monitoring devices. It applies to each additional 20-minute increment beyond the initial monthly service period. |
27 | $32 | $130 |
| Exercise stress test A test that monitors the heart and lungs while the patient exercises to evaluate their function under physical stress. |
23 | $126 | $475 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
19 | $74 | $212 |
| Remote physiologic monitoring setup and education Initial setup of remote monitoring equipment and patient education on its use. |
14 | $16 | $60 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$7,674
Total received (2018-2024)
Avg $1,096/year across 7 years
Top 25% in TX for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
31
Companies
339
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,059
2023
$1,506
2022
$1,328
2021
$376
2020
$135
2019
$1,109
2018
$1,160
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$391
GENZYME CORPORATION
$341
Regeneron Healthcare Solutions, Inc.
$251
Boehringer Ingelheim Pharmaceuticals, Inc.
$234
GlaxoSmithKline, LLC.
$227
Baxter Healthcare
$187
Actelion Pharmaceuticals US, Inc.
$144
Shionogi Inc
$88
Insmed, Inc.
$49
Inspire Medical Systems, Inc.
$33
Resmed Corp
$31
Gilead Sciences, Inc.
$22
ABBVIE INC.
$22
Grifols USA, LLC
$22
Alexion Pharmaceuticals, Inc.
$17
Top 3 companies account for 47.7% of 2024 payments
All-time payments by company (2018-2024) ›
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,541
AstraZeneca Pharmaceuticals LP
$1,468
GlaxoSmithKline, LLC.
$1,374
GENZYME CORPORATION
$711
Regeneron Healthcare Solutions, Inc.
$473
Baxter Healthcare
$370
Inspire Medical Systems, Inc.
$304
Shionogi Inc
$287
Actelion Pharmaceuticals US, Inc.
$194
Janssen Pharmaceuticals, Inc
$157
Takeda Pharmaceuticals U.S.A., Inc.
$112
ADVANCED RESPIRATORY, INC
$90
Philips Electronics North America Corporation
$67
Mylan Specialty L.P.
$58
Insmed, Inc.
$49
Electromed, Inc.
$45
ABBVIE INC.
$38
Amgen Inc.
$36
Mallinckrodt Enterprises LLC
$35
Mallinckrodt LLC
$34
Sunovion Pharmaceuticals Inc.
$33
Resmed Corp
$31
Gilead Sciences, Inc.
$22
Grifols USA, LLC
$22
Mallinckrodt Hospital Products Inc.
$21
Advanced Respiratory, Inc
$21
Ambu Inc.
$19
Genentech USA, Inc.
$19
Alexion Pharmaceuticals, Inc.
$17
PFIZER INC.
$13
Circassia Pharmaceuticals Inc
$13
Top 3 companies account for 57.1% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · AIRSENSE · AIRSUPRA · ANORO · AREXVY · AVYCAZ · Arikayce · BREO · BREZTRI · BREZTRI AEROSPHERE · DUPIXENT · ELIQUIS · FARXIGA · FASENRA · Fetroja · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · INSPIRE · Inspire Upper Airway Stimulation System · LIVTENCITY · LONHALA MAGNAIR · NUCALA · OFEV · OPSUMIT · Perforomist · Prolastin-C Liquid · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · The Vest System Model 105 Home Care · ULTOMIRIS · UPTRAVI · Utibron · Veklury · XARELTO · Xolair · Yupelri · inCourage
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Pulmonary diseases in nearby ZIP areas
136
County median income
$73,104
Nearest hospital to ZIP centroid (approximate)
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Noureddine is a clinical cardiology specialist, with above-average Medicare volume (top 21% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Noureddine experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Noureddine performed 370 hospital follow-up visit, high complexity services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Noureddine receive payments from pharmaceutical companies?
Yes. Dr. Noureddine received a total of $7,674 from 31 companies across 339 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Noureddine's costs compare to other pulmonary diseases in Houston?
Dr. Noureddine's average Medicare payment per service is $80. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Noureddine) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Houston
Browse pulmonary diseases in Houston ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in TX
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in TX
Which TX pulmonary diseases receive the most from drug and device companies.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology